Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on the development of novel therapies for inflammatory ocular diseases. The company operates within the biotechnology and pharmaceuticals industry, with a specific emphasis on ophthalmology. Its core strategy centers on identifying and advancing peptide-based drug candidates that address unmet medical needs, particularly conditions associated with ocular surface inflammation.
The company’s primary product candidate is OK-101 (formerly known as urcosimod), a novel anti-inflammatory peptide being developed for the treatment of neuropathic corneal pain and dry eye disease. OKYO Pharma positions itself as a specialist in ocular inflammatory disorders, targeting indications where existing therapies have limited efficacy or tolerability. The company was incorporated in 2007 and has evolved from a broader early-stage pharmaceutical developer into a focused ophthalmology company following strategic reprioritization of its pipeline.
Business Operations
OKYO Pharma’s operations are centered on research and clinical development rather than commercial manufacturing or product sales. The company generates no commercial revenue and funds its activities primarily through equity financing. Its business model is typical of early-stage biotechnology companies, emphasizing value creation through clinical milestones, intellectual property development, and potential future licensing or partnership opportunities.
The company’s development activities are conducted through a combination of internal management and outsourced clinical research organizations. OKYO Pharma does not currently operate manufacturing facilities and relies on third-party service providers for formulation, clinical trials, and regulatory support. Its lead program, OK-101, is being evaluated in clinical trials primarily within the United States, with regulatory oversight from the U.S. Food and Drug Administration.
Strategic Position & Investments
Strategically, OKYO Pharma is focused on advancing OK-101 through mid-stage clinical development to demonstrate safety and efficacy in ocular inflammatory conditions. The company’s growth strategy emphasizes clinical validation of its lead asset, with the intention of increasing its attractiveness for strategic partnerships, licensing arrangements, or potential acquisition by a larger pharmaceutical company specializing in ophthalmology.
The company has historically expanded its pipeline through targeted acquisitions of intellectual property rather than large-scale corporate acquisitions. Notably, OKYO Pharma acquired the rights to OK-101 from a third party, enabling it to concentrate resources on a single high-conviction asset. Beyond its lead candidate, publicly available disclosures indicate no material investments in diversified subsidiaries or unrelated therapeutic areas, reflecting a highly focused strategic posture.
Geographic Footprint
OKYO Pharma Limited is headquartered in the United Kingdom, while its operational and clinical focus is largely based in the United States, where its primary clinical trials are conducted. The company’s shares are publicly listed in the United States and the United Kingdom, providing access to international capital markets despite its limited physical footprint.
The company does not maintain extensive international offices or manufacturing sites. Instead, it exerts geographic reach through contractual relationships with clinical research organizations, regulatory consultants, and service providers across North America and Europe, supporting its clinical development and regulatory activities.
Leadership & Governance
OKYO Pharma is led by an executive team with experience in biotechnology, pharmaceuticals, and capital markets. The leadership emphasizes disciplined capital allocation, focused clinical development, and advancing assets with clear regulatory and commercial pathways in ophthalmology.
Key executives include:
- Gary S. Jacob – Chief Executive Officer
- Mark Pritchard – Non-Executive Chairman
- Julian Cooper – Chief Financial Officer
- Andrew Malin – Chief Operating Officer
- Nigel Theobald – Non-Executive Director
The board and management team collectively guide the company’s strategic vision, which centers on advancing innovative treatments for ocular inflammation while maintaining regulatory rigor and financial prudence appropriate for a clinical-stage biotechnology company.